Novo Nordisk's High-Stakes Week: CagriSema Data and Oral Wegovy's UAE Launch Test Investor Patience
05.06.2026 - 20:44:29 | boerse-global.de
It has been a bruising 12 months for Novo Nordisk. The Danish drugmaker’s stock has shed over 40% of its value even as the GLP-1 market continues to expand. This week, however, could provide the catalysts needed to shift the narrative. Two major events are competing for attention: the first international launch of the oral Wegovy pill and a pivotal pipeline readout at the American Diabetes Association (ADA) Scientific Sessions.
Oral Wegovy Touches Down in the Gulf
Since Friday, physicians in the United Arab Emirates have been able to prescribe the tablet formulation of Wegovy, marking the product’s debut outside the United States. The move brings the Danish group into direct competition with Eli Lilly, whose rival drug Foundayo has been available in the Gulf region since May. In the US, the daily pill has been a blockbuster since its January launch, with doctors issuing more than two million prescriptions to date. Analysts view the needle-free format as a key driver for expanding the obesity market to patients averse to injections.
Behind the scenes, Novo Nordisk is also shoring up its supply chain. On June 12, the company is due to open a modernised production facility in the Czech Republic, while its parent, Novo Holdings, has committed EUR 500 million to European digital health startups. At the operating level, management is deploying artificial intelligence to trim drug development timelines by up to 15%, delivering annual savings in the double-digit millions and supporting an operating margin of around 35%.
CagriSema Takes Centre Stage in New Orleans
Yet the market’s focus is increasingly fixed on the data emerging from the ADA conference, which runs from June 5-8 in New Orleans. Novo Nordisk is presenting 40 abstracts, but the headline act is the Phase 3 results for CagriSema, a fixed-dose combination of semaglutide and a long-acting amylin analogue. The drug is being studied in patients with type 2 diabetes, and analysts at William Blair have cautioned that the REIMAGINE trials will face especially close scrutiny after CagriSema failed to show non-inferiority against Lilly’s Zepbound in the head-to-head REDEFINE-4 obesity study. In that trial, CagriSema produced an average 23% weight loss after 84 weeks, compared with 25.5% for Zepbound.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Strong diabetes data could help repair some of that reputational damage. The programme also includes Phase 2 data for the injectable Zenagamtide and updates on Ozempic and Wegovy across a range of cardiometabolic indications, including cardiovascular disease, kidney disease, lung conditions, asthma, sleep apnoea and MASH. On June 7, the company will host a dedicated R&D investor event via webcast to contextualise the findings.
Meanwhile, two early-stage trials are already recruiting: a first-in-human study of NNC0497-0040 for obesity and diabetes, and another Phase 1 trial for NNC0113-5840, underscoring the depth of the pipeline beyond CagriSema.
Buybacks Support, but Analytics Remain Cautious
While the clinical side garners the headlines, Novo Nordisk has continued to return capital to shareholders. A share buyback programme of up to DKK 15 billion over twelve months is under way, with an active tranche of up to DKK 11.2 billion in B-shares running until February 2027. As of the end of May, the company had repurchased nearly 17.9 million B-shares at an average price of DKK 263.47, for a total outlay of DKK 4.71 billion.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
Nevertheless, the stock remains under pressure. At Friday’s close of EUR 37.75, the shares are down 15.5% year-to-date and trade 9.4% below their 200-day moving average, though they have clawed back 5.4% above the short-term average. The consensus of 23 Wall Street analysts stands at “Hold”, with a 12-month price target of $65.56, split between 18 hold ratings, four buys and one sell. Goldman Sachs reaffirmed a neutral stance earlier this month.
The next few days will determine whether pipeline progress and commercial expansion can reverse the stock’s slide. A strong showing for CagriSema in diabetes could narrow the gap with Eli Lilly; disappointing data would only widen it. With a new market for oral Wegovy already open and R&D spending accelerating, Novo Nordisk is playing for high stakes.
Ad
Novo Nordisk Stock: New Analysis - 5 June
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
